Bonar Bio Secures Nearly RMB 100 Million Series A Funding Led by Luxin Venture Capital to Strengthen Leadership in Membrane Separation and Purification

VCBeat has learned that Shandong Bona Biological Technology Group Co., Ltd. (hereinafter referred to as “Bona Bio”) announced the completion of its Series A financing, with a total amount nearing RMB 100 million. This round of financing was led byLuxin Venture CapitalLead Investor,Jinan Hi-Tech FinanceCo-investment,Life CapitalServed as the exclusive financial advisor. Investors in this round have strong confidence in the development prospects of Bona Bio and will support the company’s market expansion in the field of membrane separation and purification through resource empowerment and integration, thereby further strengthening Bona Bio’s leading position in this sector.

In the biopharmaceutical manufacturing process, high-end membrane separation products and equipment have been widely and effectively applied in fields such as antibodies, recombinant proteins, vaccines, blood products, and small-molecule drugs; however, imported brands still dominate China’s high-end membrane market for biomedical applications.Shandong Bona Biological Technology Group Co., Ltd. is a high-tech enterprise focused on the field of membrane separation and purification., is also a leader in the manufacturing of separation and purification equipment for the biopharmaceutical industry, and one of the earliest enterprises in China engaged in the development of advanced membrane separation application processes. Adhering to the R&D philosophy of "beginning with the end in mind" and the business model of "full lifecycle" customer management, the company has developed and applied a series of customer goal-oriented membrane material production processes, complete sets of membrane equipment manufacturing, and membrane application process development expertise through its own experimental exploration and practical verification, continuously breaking the monopoly of imported products in various industries.

Shandong Bona Biological Technology Group Co., Ltd. offers customers a comprehensive series of six major membrane elements for laboratory and industrial filtration—including organic spiral-wound membranes, organic cassettes, organic hollow fiber membranes, inorganic tubular ceramic membranes, inorganic plate-and-frame ceramic membranes, and electrodialysis membranes. Its product line meets filtration accuracy requirements across all levels, including microfiltration, ultrafiltration, nanofiltration, and reverse osmosis.Leveraging the advantages of a comprehensive product portfolio and combining the unique technical features of each product, we flexibly design and configure various filtration solutions to meet customers’ specific production and hygiene grade requirements, thereby maximizing their production benefits.

The company has remained steadfast in its mission to accelerate the domestic substitution of membrane separation and purification equipment and consumables. It consistently focuses on three core business segments: R&D of foundational membrane materials, manufacturing of high-performance membrane equipment, and development of advanced membrane application technologies. By developing cutting-edge separation and purification processes for clients, complemented by high-performance membrane equipment and cost-effective membrane consumables, the company has successfully implemented its solutions in the production of nearly 100 products across hundreds of enterprises. As a result, it has secured a strong position in the high-end segment of membrane applications within the biopharmaceutical industry, emerging as a leading manufacturer of membrane equipment in this sector.

The company continuously expands its business landscape and provides ongoing empowerment.Biopharmaceuticals, synthetic biology, food and beverages, new energy, new materials, etc.Industrial enterprises across various sectors, as well as specialized research institutes and universities. We have cumulatively helped over 4,000 clients resolve technical challenges in production and experimental processes, earning widespread acclaim from customers across industries. The successful completion of this financing round will further accelerate the localization of membrane separation equipment in China.

Qiu Fang, Deputy General Manager of Luxin Venture Capital Group Co., Ltd.Luxin Venture Capital Group Co., Ltd. stated: As a state-controlled professional venture capital firm, Luxin Venture Capital has always adhered to the philosophy of “growing together with entrepreneurial enterprises,” striving to contribute to the development of new quality productive forces and the construction of a modern industrial system. Currently, most membrane separation equipment used in China’s biomanufacturing industry relies on imported solutions. After ten years of accumulation in the field of membrane separation and purification, Shandong Bona Biological Technology Group Co., Ltd. has developed capabilities ranging from membrane material and module R&D to application process development, providing customers with end-to-end product delivery from laboratory scale to industrialization. It has become one of the few domestic solution providers capable of full-process delivery. Luxin Venture Capital will continue to support and accompany Bona Biological’s growth, empowering the high-quality development of the biomanufacturing industry.

Yang Yongbo, General Manager of Jigao Finance and Investment CompanyStatement: As an investment platform within the Jinan High-Tech Zone, JINAN HI-TECH FINACE INVESTMENT has always been committed to empowering the rapid development of technology enterprises in the zone. Shandong Bona Biological Technology Group Co., Ltd. has been deeply rooted in the Jinan High-Tech Zone for many years and is a high-quality R&D-driven enterprise in the area. The company has established a Membrane Material R&D Center and a Membrane Application Development Center. The performance of its developed membrane modules is comparable to that of imported brands, and the number of membrane application process packages it has developed far exceeds that of its peers, making it a typical early-stage “underwater project” in hard technology. We are honored to participate in this round of financing for Bona Bio. In the future, we will continue to support the enterprise, leverage the local advantages of the Jinan High-Tech Zone, continuously empower and enhance efficiency for the company, and facilitate its development.

Li Hao, Founder of Life CapitalStatement: It is a great honor to support Bona Biology in its first round of financing. Bona Biology specializes in the R&D of membrane materials, the manufacturing of membrane equipment, and the application of membrane technologies. The company has mastered the development methods for advanced inorganic membrane materials and high-performance composite membrane materials, establishing a comprehensive membrane industry chain that covers “membrane elements–membrane modules–membrane equipment–membrane applications.” Its solutions are applied across various industries, including pharmaceuticals, synthetic biology, and food and beverage. As a leading technology-driven enterprise in China that integrates advanced membrane material R&D with membrane technology applications, we believe Bona Biology will soon become a top-tier player in the domestic membrane separation and purification sector.

Luxin Venture Capital, a subsidiary of Shandong Luxin Investment Holding Group Co., Ltd., is the largest professional venture capital firm in Shandong Province and one with significant influence nationwide. It is the first venture capital institution listed on China’s capital market (Stock Code: 600783.SH). Over the past two decades since its establishment, the company has managed and operated more than 40 funds, with a total scale of approximately RMB 30 billion. Its investments span across various sectors including healthcare, military-civilian integration, advanced manufacturing, electronic information, new energy, and new materials. The portfolio includes over 40 companies listed both domestically and internationally. In the healthcare sector, it has invested in a number of outstanding enterprises such as 3D Medicines, Silicon-Based Bionics, Zhongke New Life, Abclonal, Vmai Medical, Medeast Huicheng, Instec, Colaus, and RemeGen.

Jinan Hi-Tech Finance Investment was established in April 2016. It is a state-owned sole proprietorship approved by the Administrative Committee of Jinan High-Tech Industrial Development Zone, integrating financial services such as equity investment, capital operation, leasing, guarantees, micro-lending, and factoring. The company has a registered capital of RMB 3 billion, total assets of RMB 15 billion, net assets of RMB 12 billion, and a total investment volume of approximately RMB 10 billion. It holds stakes in over 100 enterprises and has obtained an AA+ issuer credit rating. Its investment sectors include biopharmaceuticals, intelligent manufacturing, next-generation information technology, aerospace information, and quantum technology. In recent years, Jinan Hi-Tech Finance Investment has invested in several high-potential enterprises in the biopharmaceutical sector, including Shunfeng Biology, Xinchuang Biology, Longqingxiang, Microscopic Intelligence, Yingsheng Biology, Pacific Kangtai, and Guanlong Medical.

Since its establishment in 2017, the firm has operated as a boutique investment bank deeply rooted in the life sciences and broader health sectors. Upholding the mission of “Empowering Leaders in the Health Industry,” it provides strategic and capital support to industry changemakers. By leveraging strategy-driven approaches, capital services, and industrial ecosystem empowerment, the firm facilitates innovative development within the healthcare industry. Its business scope covers private equity financing, mergers and acquisitions (M&A), asset management, and industrial strategic advisory. The firm has accumulated profound expertise in niche segments such as innovative drugs, new infrastructure for biomedicine, biotechnology, synthetic biology, medical devices, digital health, consumer healthcare, and agricultural health. To date, it has completed over 60 financing transactions, with a total financing volume reaching RMB 30 billion. Life Capital will continue to refine its capabilities and resources, linking value creation to high-quality empowerment of healthcare enterprises throughout their entire lifecycle. Through diversified professional services, it aims to help businesses break through commercial constraints and drive deeper commercial and social value.